| Primary |
| Multiple Myeloma |
33.1% |
| Drug Use For Unknown Indication |
20.3% |
| Product Used For Unknown Indication |
18.4% |
| Plasma Cell Myeloma |
9.3% |
| Myelodysplastic Syndrome |
5.5% |
| Prophylaxis |
4.6% |
| Pain |
1.5% |
| Hypertension |
1.4% |
| Lymphoma |
0.8% |
| Thrombosis Prophylaxis |
0.6% |
| Amyloidosis |
0.6% |
| Nausea |
0.5% |
| Chronic Lymphocytic Leukaemia |
0.5% |
| Myelofibrosis |
0.5% |
| Constipation |
0.5% |
| Adverse Event |
0.4% |
| Non-hodgkin's Lymphoma |
0.4% |
| Acute Myeloid Leukaemia |
0.4% |
| Diabetes Mellitus |
0.3% |
| Mantle Cell Lymphoma |
0.3% |
|
| Death |
33.7% |
| Multiple Myeloma |
9.8% |
| Pneumonia |
7.6% |
| White Blood Cell Count Decreased |
4.9% |
| Thrombocytopenia |
4.4% |
| Sepsis |
3.9% |
| Plasma Cell Myeloma |
3.5% |
| Renal Failure |
3.3% |
| Platelet Count Decreased |
3.2% |
| Thrombosis |
3.1% |
| Rash |
3.0% |
| Pancytopenia |
2.9% |
| Myelodysplastic Syndrome |
2.8% |
| Disease Progression |
2.4% |
| Neutropenia |
2.2% |
| Pyrexia |
2.1% |
| Fatigue |
2.0% |
| Pulmonary Embolism |
1.7% |
| Diarrhoea |
1.7% |
| Full Blood Count Decreased |
1.7% |
|
| Secondary |
| Multiple Myeloma |
28.3% |
| Product Used For Unknown Indication |
21.5% |
| Drug Use For Unknown Indication |
16.0% |
| Prophylaxis |
13.9% |
| Plasma Cell Myeloma |
8.0% |
| Hypertension |
2.4% |
| Myelodysplastic Syndrome |
1.7% |
| Pain |
1.7% |
| Diabetes Mellitus |
0.8% |
| Thrombosis Prophylaxis |
0.8% |
| Constipation |
0.8% |
| Nausea |
0.6% |
| Insomnia |
0.5% |
| Ill-defined Disorder |
0.5% |
| Anticoagulant Therapy |
0.5% |
| Angina Pectoris |
0.4% |
| Refractory Cancer |
0.4% |
| Lymphoma |
0.4% |
| Anxiety |
0.4% |
| Antiviral Prophylaxis |
0.4% |
|
| Death |
27.3% |
| Multiple Myeloma |
11.3% |
| Pneumonia |
6.4% |
| White Blood Cell Count Decreased |
6.1% |
| Thrombocytopenia |
6.0% |
| Plasma Cell Myeloma |
5.3% |
| Platelet Count Decreased |
4.0% |
| Sepsis |
3.9% |
| Renal Failure |
3.9% |
| Rash |
2.8% |
| Pancytopenia |
2.8% |
| Pyrexia |
2.7% |
| Urinary Tract Infection |
2.4% |
| Myelodysplastic Syndrome |
2.4% |
| Blood Human Chorionic Gonadotropin Increased |
2.3% |
| Neutropenia |
2.3% |
| Renal Failure Acute |
2.1% |
| Vomiting |
2.0% |
| Diarrhoea |
1.9% |
| Weight Decreased |
1.9% |
|
| Concomitant |
| Multiple Myeloma |
39.6% |
| Product Used For Unknown Indication |
11.0% |
| Myelodysplastic Syndrome |
6.6% |
| Plasma Cell Myeloma |
5.2% |
| Drug Use For Unknown Indication |
5.2% |
| Osteoporosis |
4.5% |
| Pain |
4.5% |
| Hypertension |
3.8% |
| Neoplasm Malignant |
2.7% |
| Iron Overload |
2.7% |
| Prostate Cancer |
2.4% |
| Prophylaxis |
1.8% |
| Diabetes Mellitus |
1.5% |
| Bone Loss |
1.4% |
| Thrombosis Prophylaxis |
1.3% |
| Diarrhoea |
1.2% |
| Metastases To Bone |
1.2% |
| Nausea |
1.2% |
| Osteoarthritis |
1.2% |
| Anaemia |
1.1% |
|
| Weight Decreased |
24.1% |
| Vomiting |
7.6% |
| Tooth Extraction |
6.8% |
| Weight Increased |
6.6% |
| Wound Drainage |
6.2% |
| Wheezing |
5.4% |
| Osteonecrosis Of Jaw |
4.4% |
| Thrombocytopenia |
4.4% |
| Rash |
3.8% |
| Urinary Tract Infection |
3.8% |
| Osteonecrosis |
3.6% |
| Death |
3.2% |
| Pneumonia |
3.0% |
| White Blood Cell Count Decreased |
3.0% |
| X-ray Abnormal |
2.8% |
| Nausea |
2.6% |
| Vertebroplasty |
2.6% |
| Haemoglobin Decreased |
2.2% |
| Pyrexia |
2.2% |
| Sepsis |
2.2% |
|
| Interacting |
| Drug Use For Unknown Indication |
26.3% |
| Multiple Myeloma |
26.3% |
| Ill-defined Disorder |
7.9% |
| Blood Cholesterol Abnormal |
5.3% |
| Blood Pressure |
5.3% |
| Depression |
5.3% |
| Laxative Supportive Care |
5.3% |
| Thyroid Therapy |
5.3% |
| Convulsion |
2.6% |
| Obsessive-compulsive Personality Disorder |
2.6% |
| Pain |
2.6% |
| Plasma Cell Myeloma |
2.6% |
| Product Used For Unknown Indication |
2.6% |
|
| Paraesthesia |
16.7% |
| Serotonin Syndrome |
16.7% |
| Drug Interaction |
8.3% |
| Dry Skin |
8.3% |
| Fatigue |
8.3% |
| Inappropriate Antidiuretic Hormone Secretion |
8.3% |
| Muscle Spasms |
8.3% |
| Rash Generalised |
8.3% |
| Renal Impairment |
8.3% |
| Vertigo |
8.3% |
|
